Insider buying last 90 days
No open-market insider purchases were filed for LNTH in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Lantheus moves this week on a cluster of corporate news. The company reported third-quarter 2026 results, with worldwide revenue up 1.5% to $389.9 million and earnings beating estimates by $0.42, EPS of $1.68 against a projected $1.26. Alongside results, Lantheus detailed a definitive agreement to merge with Curium in an all-cash transaction valued at up to approximately $8.0 billion, announced FDA approvals for TAUKLARIFY and BRAVNETSA, and welcomed the CMS Calendar Year 2027 final rule preserving separate payment for diagnostic radiopharmaceuticals and extending Transitional Pass-Through status for PYLARIFY TruVu through September 30, 2029. Separately, PharmaLogic Holdings Corp. agreed to acquire Lantheus' CDMO business and its Springfield, New Jersey manufacturing facility.
Shares close at $101.01, up 0.4% on the day, sitting above both the 50-day average of $100.28 and the 200-day average of $92.42. The GekkoIndex reads 51.4, placing the stock in the Neutral zone. Price remains 34.1% below Gekko Fair Value of $153.3.
The next earnings date is set for 25 February 2027, 102 days away, placing it outside a typical 20-trading-day holding period. Current data shows no insider, Congress or unusual options activity in the recent windows, and no billionaire holders recorded, with trailblazer holders at 0. Analyst coverage stands at three firms, all rated hold, with a consensus target of $106.99. Seasonality from this point in the calendar has averaged a 4.9% gain over the next 20 trading days across 5 years, rising in 2 of them.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Lantheus scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
Above 50 and 200-day
Close $101.59 is above the 50-day ($100.32) and 200-day ($93.11) averages, and the 50-day is above the 200-day.
See the chart48.9, Neutral
Reading 48.9 is in the Neutral zone.
See the GekkoIndex41.0% below
Price is 41% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 102 days
Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.
See earnings+7.5% on average
From this point in the calendar, the next 20 trading days averaged +7.5% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Lantheus closed at $101.59 on Nov 13, 2026, +86.4% over the past year, inside a 52-week range of $51.47 to $111.86.
Use the left and right arrow keys to read daily values.
Put LNTH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Lantheus develops, manufactures and sells diagnostic and therapeutic agents used by clinicians to identify and treat conditions such as heart disease and cancer. Its diagnostic lineup includes DEFINITY for cardiac ultrasound imaging, TechneLite and Cardiolite for nuclear medicine, Xenon-133 for lung function testing, Neurolite for locating stroke damage, Thallium-201 for cardiovascular detection, Gallium-67 for spotting infection and tumors, and PYLARIFY, used to find recurrent or spreading prostate cancer. It is also associated with the Automated Bone Scan Index for measuring prostate cancer in bone scans.
Beyond diagnostics, the company markets AZEDRA, a radiopharmaceutical therapy for adult and pediatric patients, and RELISTOR, used for opioid-induced constipation. Its pipeline covers agents still in development, including flurpiridaz F 18 for blood flow assessment, 1095 and LMI 1195 for tumor targeting, PYLARIFY AI software for analyzing prostate cancer scans, and leronlimab, an antibody under investigation. Customers include radiopharmacies, distributors, hospitals, clinics, integrated delivery networks and group practices, and the company works with partners such as GE Healthcare, Bayer, Curium, FUJIFILM and Regeneron, among others.
Lantheus was established in 1956 and is headquartered in North Billerica, Massachusetts. Its shares are listed on the NASDAQ under the ticker LNTH.
Lantheus’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 48.9, in the Neutral zone, down 4.3 points over five sessions.
Down 4.3 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 39 | −0.4% | +5.1% | ||
| Accumulation | 196 | +0.9% | +3.9% | ||
| Neutral (current zone) | 422 | +0.8% | +2.5% | ||
| Distribution | 37 | +0.9% | +0.4% | ||
| Selling | 8 | Too few readings yet | |||
Average LNTH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Lantheus trades 41.0% below Gekko Fair Value of $172.19, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Lantheus shares are worth, recalculated every trading day.
$172.19
Gekko Fair Value, Nov 14, 2026
41.0% Undervalued
At the end of Aug 2026 the price was 4.7% below the estimate.
No open-market insider purchases were filed for Lantheus, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for LNTH in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in LNTH were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Lantheus has been buying back its own shares.
From company filings.
0of the funds Gekko tracks hold LNTH.
Lantheus reports on Feb 25, 2027, before the open (102 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 25, 2027
Expected before the open, 102 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $1.55 est $1.30 | $388.2M est $363.2M | −0.5% |
| May 7, 2026 | $1.46 est $1.25 | $377.3M est $354.5M | +8.0% |
| Feb 26, 2026 | $1.67 est $1.18 | $406.8M est $367.0M | −1.1% |
| Nov 6, 2025 | $1.27 est $1.27 | $384.0M est $368.0M | −10.8% |
| Aug 6, 2025 | $1.57 est $1.64 | $378.0M est $363.3M | −24.5% |
| May 7, 2025 | $1.53 est $1.68 | $372.8M est $395.2M | −23.3% |
| Feb 26, 2025 | $1.59 est $1.58 | $391.1M est $379.5M | +14.3% |
| Nov 6, 2024 | $1.70 est $1.56 | $378.7M est $375.9M | −23.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Lantheus is $105.99, +4.3% from the last close, from 2 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 2 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 13 | Mizuho Securities | $109 | +7.3% |
| Aug 17 | B. Riley Securities | $105.40 | +3.8% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Lantheus averaged +7.5% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.2% | 3 of 5 |
| Next 10 trading days | +4.6% | 4 of 5 |
| Next 15 trading days | +5.2% | 3 of 5 |
| Next 20 trading days | +7.5% | 3 of 5 |
| Next 30 trading days | +3.8% | 3 of 5 |
For scale, LNTH’s typical 20-trading-day move in either direction is about 8.9%.
Lantheus’s market cap is $6.64B, with a P/E ratio of 25.3 and revenue of $1.56B over the last twelve months.
Coverage of Lantheus this week reads positive: 4 positive, 3 neutral and 0 negative headlines.
Lantheus’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
Lantheus’s market cap is $6.64B at the Nov 13, 2026 close of $101.59, with 65.40M shares outstanding. The shares trade on a P/E ratio of 25.3.
The consensus analyst 12-month price target for Lantheus is $105.99, +4.3% from the last close. Of the 2 firms that rated the stock in the last 90 days, 0 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Lantheus is undervalued: the Nov 13, 2026 close of $101.59 is 41.0% below Gekko Fair Value of $172.19. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Lantheus is expected to report on Feb 25, 2027, before the market opens (102 days away). Analysts expect earnings of $1.31 per share on revenue of $373.3M. Lantheus beat the earnings estimate in 5 of its last 8 reports, moving 13.2% on average across the report.
Lantheus’s 52-week high is $111.86 and its 52-week low is $51.47; it closed at $101.59 on Nov 13, 2026, +86.4% over the past year. Over the last five years the shares peaked at $126.89 on Jul 16, 2024.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (trend, fair value, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.